Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4157 - A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS)


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Tumour Site

Urothelial Cancer


Daniel Castellano


Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283


D. Castellano1, I. Duran Martinez2, A. Rodríguez-Vida3, S.J. Crabb4, M.S. van der Heijden5, A. Font Pous6, G. Gravis7, U. Anido Herranz8, A. Protheroe9, A. Ravaud10, D. Maillet11, M.J. Mendez-Vidal12, C. Suarez13, A. Lorch14, C.N. Sternberg15, M. Linch16, S. Sarker17, J. Notta17, K. Mousa17, T.B. Powles17

Author affiliations

  • 1 Medical Oncology Department, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 2 Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 3 Medical Oncology, Hospital del Mar, 28023 - Barcelona/ES
  • 4 Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton/GB
  • 5 Medical Oncology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 6 Medical Oncology, Institut Català d' Oncologia, 8916 - Badalona/ES
  • 7 Medical Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 8 Medical Oncology Department, Hospital Clínico Universitario de Santiago de Compostela, 15785 - Santiago de Compostela/ES
  • 9 Medical Oncology Department, Churchill Hospital University of Oxford, OX3 7LE - Oxford/GB
  • 10 Medical Oncology Department, CHU Bordeaux Hopital St. André, 33000 - Bordeaux/FR
  • 11 Medical Oncology Department, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 12 Medical Oncology Department, Reina Sofia University Hospital, 14004 - Cordoba/ES
  • 13 Oncology, Vall d’Hebron University Hospital, Barcelona/ES
  • 14 Genitourinary Medical Oncology, Universitätsklinikum Düsseldorf, 40255 - Düsseldorf/DE
  • 15 Medical Oncology, San Camillo Forlanini Hospital, 00152 - Rome/IT
  • 16 Medical Oncology Department, UCL Cancer Institute/Paul O'Gorman Building, WC1E 6DD - London/GB
  • 17 Barts Cancer Institute, Queen Mary University of London, EC1M 6BQ - London/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4157


Atezolizumab is a PD-L1 inhibitor, which is licenced in metastatic urothelial cancer. This study investigates the efficacy and safety of neoadjuvant atezolizumab given prior to cystectomy in operable muscle invasive transitional cell carcinoma of the bladder.


This single arm phase 2 study investigated 2 cycles of atezolizumab (1200mg Q3) prior to cystectomy in muscle invasive transitional cell cancer (T2-4N0M0). Pathological complete response (pCR) occurring in ≥ 20% of patients was the primary endpoint. Biomarker analysis on sequential tissue was a co-primary endpoint. Cross sectional imaging was performed at baseline and prior to cystectomy which occurred 4 - 8 weeks after starting atezolizumab. Radiological response was assessed. Adverse events (AEs) and surgical complications were assessed using CTCAE v4.03 and the Clavien-Dindo classification. Updated analysis with 75 patients will be presented. IMCORE provided biomarker analysis.


At baseline pT2, T3, T4 disease occurred in 73%, 20% and 7% of patients respectively. 16 (21%) patients had only 1 cycle (9 due to AEs). 7 patients did not have cystectomy (1 disease progression, 2 treatment related AE). There was 1 potential treatment related death during treatment/perioperative period (cardiovascular disease). Treatment related grade 3/4 toxicity occurred in 12% of patients. Grade 3 or 4 surgical complications occurred in 31% of pt. The pCR rate was 20/68 (29%) [95%CI: 19% to 42%] (pT0 24%, Tis 6%, T1 9% T2 24% T3 22% T4 15% stage at surgery). 39% of patients were down staged to non-muscle invasive disease. 3/20 (15%) of the pCR patients had pT3/4 disease at baseline. 47% patients were positive for PD-L1 (≥5% IC SP142); pCR rates were 38% and 27% in PD-L1 positive and negative tumours respectively (n = 62). 47 patients had sequential imaging and radiologically measurable disease at baseline. 28% [95%CI, 16% to 43%] and 17% [95%CI, 8% to 31%] of these patients radiologically responded and progressed respectively.


Neoadjuvant atezolizumab is safe and associated with a meaningful pathological CR rate at this interim stage. Further exploration is justified.

Clinical trial identification


Legal entity responsible for the study

Queen Mary University of London.


F. Hoffmann - La Roche Ltd.

Editorial Acknowledgement


I. Duran: Consulting or advisory role: roche/Genentech, MSD Oncology, Bayer, Bristol-Myers Squibb; Travel, accommodation, expenses: Roche/Genentech; Honoraria: Bristol-Myers Squibb, Ipsen, Roche/Genentech; Research funding: Roche/Genentech (institution). S.J. Crabb: Consulting or Advisory role: Roche, Clovis Oncology, Bayer, Janssen-Cilag; Travel, accommodation, expenses: Bayer, Merck, Ipsen, Bristol-Myers Squibb, Roche, Janssen-Cilag; Honoraria: Novartis, Roche, Janssen-Cilag; Research funding: AstraZeneca, Astex Pharmaceuticals, Plexxikon, Clovis Oncology. M.S. van der Heijden: Consulting or advisory role (institution): Roche/Genentech, Astellas Pharma, AstraZeneca/MedImmune, Bristol-Myers Squibb; Travel, accommodation, expenses: Novartis, Astellas Pharma, MSD Oncology; Research funding: Astellas Pharma (institution). G. Gravis: Travel, accommodation, expenses: Novartis, Sanofi, Janssen Oncology, Bristol-Myers Squibb, Astellas Pharma, Takeda. U. Anido Herranz: Consulting or advisory role: Bayer; Travel, accommodation, expenses: Astellas Pharma; Honoraria: Pfizer, Novartis, Bayer. A. Ravaud: Consulting or advisory role: Pfizer, Novartis, Bristol-Myers Squibb, Ipsen, Roche; Travel, accommodation, expenses: Pfizer, Novartis, Bristol-Myers Squibb; Honoraria: Pfizer, Bristol-Myers Squibb, Novartis; Research funding (institution): Pfizer, Novartis. C. Suarez: Consulting or advisory role: Bristol-Myers Squibb, Ipsen, Sanofi, Pfizer; Travel, accommodation, expenses: Bristol-Myers Squibb; Honoraria: Roche. A. Lorch: Consulting or advisory role: Bristol-Myers Squibb, Novartis, AstraZeneca, Roche; Travel, accommodation, expenses: Novartis, Ipsen; Honoraria: Astellas Scientific and Medical Affairs Inc, Ipsen. C.N. Sternberg: Consulting or advisory role: Bristol-Myers Squibb, Novartis, Janssen, Bayer, Eisai, MSD, Lilly, Clovis Oncology, Ferring; Honoraria: Pfizer, Astellas Pharma, Sanofi, Ipsen, AstraZeneca. T.B. Powles: Consulting or advisory role: Roche/Genentech, Bristol-Myers Squibb, Merck, Novartis, AstraZeneca; Honoraria: Roche/Genentech, Bristol-Myers Squibb, Merck; Research funding: AstraZeneca/MedImmune, Roche/Genentech; Other relationship: Ipsen, Bristol-Myers Squibb. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.